Hormonal carcinogenesis in women: from mechanisms to prevention;Cancérogenèse hormonale chez la femme : des mécanismes à la prévention

Comptes Rendus - Biologies

Volumn 331, Issue 2, 2008, Pages 104-113

  Rochefort, Henri ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Anti estrogens; Breast cancer; Carcinogenesis; Cathepsin D; Fatty acid synthase; Oestrogen receptors; Progesterone receptor; Proliferative mastopathia

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; CATHEPSIN D; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; HORMONE RECEPTOR; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN;

CANCER; CARCINOGEN; ENDOCRINOLOGY; HORMONE; MEDICINE; PUBLIC HEALTH; RISK FACTOR; TUMOR; WOMENS HEALTH;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; DRUG EFFICACY; ESTROGEN ACTIVITY; HORMONAL CARCINOGENESIS; HORMONE DEPENDENCE; HORMONE SENSITIVITY; HUMAN; IMMUNOFLUORESCENCE TEST; MENOPAUSAL SYNDROME; PRECANCER; PROTEIN EXPRESSION; PUBLIC HEALTH; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR PROMOTION; WOMEN'S HEALTH;

BREAST NEOPLASMS; CARCINOGENS; ESTROGENS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MUTATION; NEOPLASM STAGING; PROGESTINS; RISK FACTORS;

EID: 38549141180     PISSN: 16310691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crvi.2006.07.009     Document Type: Short Survey

References (50)

1. Hill C., and Doyon F. La fréquence des cancers en France en 2002 et son évolution depuis 1968. Bull. Cancer 93 (2006) 7-11
2. Pike M.C., Pearce C.L., and Wu A.H. Prevention of cancers of the breast, endometrium and ovary. Oncogene 23 (2004) 6379-6391
3. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrinol. Rev. 25 (2004) 45-71
4. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 24 (2003) 643-646
5. Rebbeck T.R. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur. J. Cancer 38 Suppl. 6 (2002) S15-S17
6. Lacassagne A. Apparition de cancers de la mamelle chez la souris mâle soumise à l'injection de folliculine. C. R. Acad. Sci. Paris 195 (1932) 630-636
7. Hulka B.S., and Stark A.T. Breast cancer cause and prevention. Lancet 346 (1995) 883-887
8. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 8 (2004) 789-799
9. Folkman J., and Kallurl R. Cancer without disease. Nature 427 (2004) 787
10. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J. Am. Med. Assoc. 288 (2002) 321-333
11. Rochefort H., and Sureau C. Les traitements hormonaux substitutifs (TSH) de la ménopause : évolution récente du rapport bénéfices/risques. Bull. Acad. Natl. Med. 187 (2003) 1707-1711. et www.academie-medecine.fr/ (séance du 02/12/2003)
12. Cogliano V., Grosse Y., Baan R., Straif K., Secretan B., El Ghissassi F., and WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. (August 2005) 552-553
13. Henderson B.E., and Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 21 3 (2000) 427-433
14. Herbst A.L., and Bern H.A. Developmental Effects of Diethylstilboestrol (DES) in Pregnancy (1988), Thieme-Stratton, New York
15. Yue W., Santen R.J., Wang J.-P., Li Y., Verderame M.F., Bocchinfuso W.P., Korach K.S., Devanesan P., Todorovic R., Rogan E.G., and Cavalieri E.L. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J. Steroid Biochem. Mol. Biol. 86 (2003) 477-486
16. Rochefort H., and Maudelonde T. Les Antiœstrogènes (1989), Flammarion Médecine-Sciences, Paris
17. Chambon P. Le récepteur des œstrogènes : de sa structure à sa fonction. Ann. Inst. Pasteur 1 (1992) 51-61
18. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engström O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
19. Pike A.C.W., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.G., Engström O., Ljunggren J., Gustafsson J.A., and Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18 (1999) 4608-4618
20. Lippman M.E., Bolan G., and Huff K. The effects of estrogens and anti-estrogens on hormone responsive human breast cancer in long-term issue culture. Cancer Res. 36 (1976) 4595-4601
21. Chalbos D., Vignon F., Keydar I., and Rochefort H. Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J. Clin. Endocrinol. Metab. 55 (1982) 276-283
22. Rochefort H. Estrogen-induced genes in breast cancer and their medical importance. Bull. Acad. Natl. Med. 183 5 (1999) 955-968 (discussion: 968-971)
23. Pestell R.G., Albanese C., Reutens A.T., Segall J.E., Lee R.J., and Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr. Rev. 20 4 (1999) 501-534
24. Gustafsson J.A. Estrogen receptor β. J. Endocrinol. 163 (1999) 379-383
25. McKenna N.J., and O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 (2002) 465-474
26. Howell A., Howell S.J., and Evans D.G. New approaches to the endocrine prevention and treatment of breast cancer. Cancer Chemother. Pharmacol. 52 (2003) S39-S44
27. Writing Group for the Women's Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J. Am. Med. Assoc. 291 (2004) 1701-1712
28. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 9382 (2003) 419-427
29. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer 114 (2005) 448-454
30. Vignon F., Bardon S., Chalbos D., and Rochefort H. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J. Clin. Endocrinol. Metab. 56 (1983) 1124-1130
31. Chalbos D., Escot C., Joyeux C., Tissot-Carayon M.-J., Pages A., and Rochefort H. Expression of the progestin-induce fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridisation. J. Natl. Cancer Inst. 82 7 (1990) 602-606
32. Rochefort H. Do antiestrogens and antiprogestins act as hormone antagonists or receptor-targeted drugs in breast cancer?. Trends Pharmacol. Sci. 8 (1987) 126-128
33. Rangarajan A., and Weinberg R.A. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer 3 (2003) 952-959
34. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., Richardson A., and Weinberg R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101 (2004) 4966-4971
35. Clarke R.B., Spence K., Anderson E., Howell A., Okano H., and Potten C.S. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 57 (1997) 4987-4991
36. Clarke R.B., Howell A., Potten C.S., and Anderson E. A putative breast stem cell population is enriched for steroid receptor positive cells. Dev. Biol. 277 (2005) 443-456
37. Roger P., Daures J.-P., Maudelonde T., Pignodel C., Gleizes M., Chapelle J., Marty-Double C., Baldet P., Mares P., Laffargue F., and Rochefort H. Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. Hum. Pathol. 31 (2000) 593-600
38. Dupont W.D., and Page D.L. Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med. 312 3 (1985) 146-151
39. Roger P., Esslimani Sahla M., Makela S., Gustafsson J.A., Baldet P., and Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 61 (2001) 2537-2541
40. Palmieri C., Cheng G.J., Saji S., Zelada-Hedman M., Warri A., Weihua Z., Van Noorden S., Wahlstrom T., Coombes R.C., Warner M., and Gustafsson J.A. Estrogen receptor beta in breast cancer. Endocr. Relat. Cancer 9 1 (2002) 1-13
41. Cheng G., Li Y., Omoto Y., Wang Y., Berg T., Nord M., Vihko P., Warner M., Piao Y.S., and Gustafsson J.A. Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. J. Clin. Endocrinol. Metab. 1 (2005) 435-444
42. Zhao C., Lam E.W., Sunters A., Enmark E., De Bella M.T., Coombes R.C., Gustafsson J.A., and Dahlman-Wright K. Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22 (2003) 7600-7606
43. Esslimani Sahla M., Kramar A., Simony Lafontaine J., Warner M., Gustafsson J.A., and Rochefort H. Increased estrogen receptor beta cx expression during mammary carcinogenesis. Clin. Cancer Res. 11 (2005) 3170-3174
44. Esslimani-Sahla M., Thezenas S., Simony-Lafontaine J., Kramar A., Lavaill R., Chalbos D., and Rochefort H. Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int. J. Cancer 120 (2007) 224-229
45. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., and Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100 14 (2003) 8418-8423
46. Simpson P.T., Reis-Filho J.S., Gale T., and Lakhani S.R. Molecular evolution of breast cancer. J. Pathol. 205 (2005) 248-254
47. Rochefort H., Garcia M., Glondu M., Laurent V., Liaudet E., Rey J.M., and Roger P. Cathepsin D in breast cancer: mechanisms and clinical applications a 1999 overview. Clin. Chim. Acta 291 (2000) 157-170
48. Cuzick J. Aromatase inhibitors for breast cancer prevention. J. Clin. Oncol. 23 8 (2005) 1636-1643
49. Martino S., Cauley J.A., Barrett-Connor E., Powles T.J., Mershon J., Disch D., Secrest R.J., and Cummings S.R. CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst. 96 23 (2004) 1751-1761
50. Russo J., Mailo D., Hu Y.F., Balogh G., Sheriff F., and Russo I.H. Breast differentiation and its implication in cancer prevention. Clin. Cancer Res. 11 (2005) 931-936